Action and therapeutic potential of oxyntomodulin

Molecular Metabolism

Volumn 3, Issue 3, 2014, Pages 241-251

  Pocai, Alessandro ^a  

^a Janssen Research and Development   (United States)

Author keywords

Body weight; GLP 1; Glucagon; Glucose metabolism; Oxyntomodulin

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; OXYNTOMODULIN;

BODY WEIGHT; CARDIOVASCULAR DISEASE; CELL HYPERPLASIA; DIABETES MELLITUS; DISORDERS OF CARBOXYLIC ACID METABOLISM; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; FAT FREE MASS; FOOD INTAKE; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; LIPID BLOOD LEVEL; NONHUMAN; OBESITY; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

EID: 84897116945     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.12.001     Document Type: Review

References (149)

1. UKPDS U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44:1249-1258. 10.2337/diabetes.44.11.1249.
2. Bray G.A. Medical consequences of obesity. Journal of Clinical Endocrinology and Metabolism 2004, 89:2583-2589. 10.1210/jc.2004-0535.
3. Holst J.J. Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Regulatory Peptides 2000, 93:45-51. 10.1016/S0167-0115(00)00185-3.
4. Hansen L., Hartmann B., Bisgaard T., Mineo H., Jørgensen P.N., Holst J.J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology - Endocrinology and Metabolism 2000, 278(6):E1010-E1018.
5. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
6. Meier J.J., Gallwitz B., Salmen S., Goetze O., Holst J.J., Schmidt W.E., et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2003, 88:2719-2725.
7. Meier J.J., Kemmeries G., Holst J.J., Nauck M.A. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005, 54:2212-2218. 10.2337/diabetes.54.7.2212.
8. Nauck M.A., Kemmeries G., Holst J.J., Meier J.J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60:1561-1565. 10.2337/db10-0474.
9. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Journal of the American Medical Association 2007, 298:194-206. 10.1001/jama.298.2.194.
10. Nauck M.A., Sauerwald A., Ritzel R., Holst J.J., Schmiegel W. Influence of glucagon-like peptide-1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998, 21:1925-1931.
11. Kim J.Y., Lim D.M., Park H.S., Moon C.I., Choi K.J., Lee S.K., et al. Exendin-4 protects against sulfonylurea-induced β-cell apoptosis. Journal of Pharmacological Science 2012, 118:65-74.
12. Drucker D.J. Biologic actions and therapeutic potential of the glucagon-like peptides. Nature Clinical Practice. Endocrinology and Metabolism 2005, 1:22-31. 10.1038/ncpendmet0017.
13. Ghatei M.A., Uttenthal L.O., Christofides N.D., Bryant M.G., Bloom S.R. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. Journal of Clinical Endocrinology and Metabolism 1983, 57:488-495. 10.1210/jcem-57-3-488.
14. Holst J.J. Enteroglucagon. Annual Review of Physiology 1997, 59:257-271. 10.1146/annurev.physiol.59.1.257.
15. Le Quellec A., Kervran A., Blache P., Ciurana A.J., Bataille D. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. Journal of Clinical Endocrinology and Metabolism 1992, 74:1405-1409. 10.1210/jc.74.6.1405.
16. Furuta M., Zhou A., Webb G., Carroll R., Ravazzola M., Orci L., Steiner D.F. Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. Journal of Biological Chemistry 2001, 276:27197-27202. 10.1074/jbc.M103362200.
17. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocrine Reviews 1999, 20:876-913. 10.1210/er.20.6.876.
18. Rouille Y., Westermark G., Martin S.K., Steiner D.F. Proglucagon is processed to glucagon by prohormone convertase PC2 in a TC1-6 cells. Proceedings of the National Academy of Sciences 1994, 91:3242-3246. 10.1073/pnas.91.8.3242.
19. Brubaker P.L. A beautiful cell (or two or three?). Endocrinology 2012, 153:2945-2948. 10.1210/en.2012-1549.
20. Habib A.M., Richards P., Cairns L.S., Rogers G.J., Bannon C.A., Parker, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 2012, 153:3054-3065. 10.1210/en.2011-2170.
21. Sutherland E.W., De Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. Journal of Biological Chemistry 1948, 175:663-674.
22. Unger R.H., Eisentraut A.M., McCall M.S., Keller S., Lanz H.C., Madison L.L. Glucagon antibodies and their use for immunoassay for glucagon. Proceedings of the Society for Experimental Biology and Medicine 1959, 102:621-623.
23. Bataille D., Gespach C., Coudray A.M., Rosselin G. 'Enteroglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence foran 'oxyntomodulin' action. Bioscience Reports 1981, 1:151-155. 10.1007/BF01117012.
24. Bataille D., Gespach C., Tatemoto K., Marie J.C., Coudray A.M., Rosselin G., et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 1981, 2(Suppl. 2):S41-S44. 10.1016/0196-9781(81)90008-5.
25. Bataille D., Tatemoto K., Coudray A.M., Rosselin G., Mutt V. Bioactive 'enteroglucagon' (oxyntomodulin): evidence for a C-terminal extension of the glucagon molecule. Comptes Rendus des Séances de l'Académie des Sciences. Série III 1981, 293:323-328.
26. Bataille D., Tatemoto K., Gespach C., Jornvall H., Rosselin G., Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Letters 1982, 146:79-86. 10.1016/0014-5793(82)80709-6.
27. Baldissera F.G., Holst J.J., Knuhtsen S., Hilsted L., Nielsen O.V. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regulatory Peptides 1988, 21:151-166. 10.1016/0167-0115(88)90099-7.
28. Gros L., Thorens B., Bataille D., Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993, 133:631-638. 10.1210/en.133.2.631.
29. Pocai A., Carrington P.E., Adams J.R., Wright M., Eiermann G., Zhu L., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009, 58:2258-2266. 10.2337/db09-0278.
30. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558. 10.1053/j.gastro.2004.04.063.
31. Jorgensen R., Kubale V., Vrecl M., Schwartz T.W., Elling C.E. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor b-arrestin recruitment and signaling through Gα(s). Journal of Pharmacology and Experimental Therapeutics 2007, 322:148-154. 10.1124/jpet.107.120006.
32. Schepp W., Dehne K., Riedel T., Schmidtler J., Schaffer K., Classen M. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 1996, 57:398-405. 10.1159/000201367.
33. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., Ghatei M.A., Bloom S.R. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004, 145:2687-2695. 10.1210/en.2003-1338.
34. Chaudhri O.B., Parkinson J.R., Kuo Y.T., Druce M.R., Herlihy A.H., Bell J.D., et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochemical and Biophysical Research Communications 2006, 350:298-306. 10.1016/j.bbrc.2006.09.033.
35. Parkinson J.R., Chaudhri O.B., Kuo Y.T., Field B.C., Herlihy A.H., Dhillo W.S., Ghatei M.A., et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). NeuroImage 2009, 44:1022-1031. 10.1016/j.neuroimage.2008.09.047.
36. Parker J.A., McCullough K.A., Field B.C., Minnion J.S., Martin N.M., Ghatei M.A., et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. International Journal of Obesity (London) 2013, 37:1391-1398. 10.1038/ijo.2012.227.
37. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. Journal of Clinical Endocrinology and Metabolism 2003, 88:4696-4701.
38. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54:2390-2395. 10.2337/diabetes.54.8.2390.
39. Dakin C.L., Gunn I., Small C.J., Edwards C.M., Hay D.L., Smith D.M., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001, 142:4244-4250. 10.1210/en.142.10.4244.
40. Dakin C.L., Small C.J., Park A.J., Seth A., Ghatei M.A., Bloom S.R. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. American Journal of Physiology - Endocrinology and Metabolism 2002, 283:E1173-E1177.
41. Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. Journal of Endocrinology 2012, 215:335-346. 10.1530/JOE-12-0368.
42. Holst J.J., Sorensen T.I., Andersen A.N., Stadil F., Andersen B., Lauritsen K.B., et al. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scandinavian Journal of Gastroenterology 1979, 14:205-207. 10.3109/00365527909179871.
43. Besterman H.S., Cook G.C., Sarson D.L., Christofides N.D., Bryant M.G., Gregor M., et al. Gut hormones in tropical malabsorption. British Medical Journal 1979, 2:1252-1255. 10.1136/bmj.2.6200.1252.
44. Besterman H.S., Adrian T.E., Mallinson C.N., Christofides N.D., Sarson D.L., Pera A., et al. Gut hormone release after intestinal resection. Gut 1982, 23:854-861. 10.1136/gut.23.10.854.
45. Du X., Kosinski J.R., Lao J., Shen X., Petrov A., Chicchi G.G., et al. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. American Journal of Physiology - Endocrinology and Metabolism 2012, 303:E265-E271. 10.1152/ajpendo.00142.2012.
46. Kosinski J.R., Hubert J., Carrington P.E., Chicchi G.G., Mu J., Miller C., et al. The glucagon receptor is involved in mediating the body weight lowering effects of oxyntomodulin. Obesity 2012, 20:1566-1571. 10.1038/oby.2012.67.
47. Santoprete A., Capito E., Carrington P.E., Pocai A., Finotto M., Langella A., et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. Journal of Peptide Science 2011, 17:270-280. 10.1002/psc.1328.
48. Maida A., Lovshin J.A., Baggio L.L., Drucker D.J. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008, 149:5670-5678. 10.1210/en.2008-0336.
49. Parlevliet E.T., Heijboer A.C., Schroder-van der Elst J.P., Havekes L.M., Romijn J.A., Pijl H., et al. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. American Journal of Physiology - Endocrinology and Metabolism 2008, 294:E142-E147. 10.1152/ajpendo.00576.2007.
50. Shankar S.S., Shankar R.R., Mixson L., Pramanik B.S., Stoch A., Steinberg H.O., et al. Oxyntomodulin has significant acute glucoregulatory effects comparable to liraglutide in subjects with type 2 diabetes. Diabetes 2013, 62(Suppl. 1):A48. 10.2337/db13-1-387.
51. Wynne K., Park A.J., Small C.J., Meeran K., Ghatei M.A., Frost G.S., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial. International Journal of Obesity 2006, 30:1729-1736. 10.1038/sj.ijo.0803344.
52. Schjoldager B.T., Baldissera F.G., Mortensen P.E., Holst J.J., Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. European Journal of Clinical Investigation 1988, 18:499-503. 10.1111/j.1365-2362.1988.tb01046.x.
53. Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Digestive Diseases and Sciences 1989, 34(9):1411-1419.
54. Sowden G.L., Drucker D.J., Weinshenker D., Swoap S.J. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2007, 292:R962-R970.
55. Wynne K., Field B.C., Bloom S.R. The mechanism of action for oxyntomodulin in the regulation of obesity. Current Opinion in Investigational Drugs 2010, 11:1151-1157. (Review).
56. Habegger K.M., Heppner K.M., Geary N., Bartness T.J., DiMarchi R., Tschop M.H. The metabolic actions of glucagon revisited. Nature Reviews. Endocrinology 2010, 6:689-697. 10.1038/nrendo.2010.187.
57. Mighiu P.I., Yue J.T., Filippi B.M., Abraham M.A., Chari M., Lam C.K., et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nature Medicine 2013, 19:766-772. 10.1038/nm.3115.
58. Anini Y., Jarrousse C., Chariot J., Nagain C., Yanaihara N., Sasaki K., Bernad N., Le Nguyen D., Bataille D., Rozé C. Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats. Pancreas 2000, 20:348-360.
59. Schapiro H., Ludewig R.M. The effect of glucagon on the exocrine pancreas. American Journal of Gastroenterology 1978, 70:274-281. (Review).
60. Collie N.L., Zhu Z., Jordan S., Reeve Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology 1997, 112:1961-1970.
61. Stümpel F., Scholtka B., Hunger A., Jungermann K. Enteric glucagon 37 rather than pancreatic glucagon 29 stimulates glucose absorption in rat intestine. Gastroenterology 1998, 115:1163-1171.
62. Cheeseman C.I., Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. American Journal of Physiology 1996, 271:G477-G482.
63. Cheeseman C.I. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. American Journal of Physiology 1997, 273:R1965-R1971.
64. Lagerström M.C., Schiöth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Reviews Drug Discovery 2008, 7:339-357. (Review). 10.1038/nrd2518.
65. Siu F.Y., He M., de Graaf C., Han G.W., Yang D., Zhang Z., et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 2013, 499:444-449. 10.1038/nature12393.
66. Plamboeck A., Veedfald S., Deacon C.F., Hartmann B., Wettergren A., Svendsen L.B., et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology - Gastrointestinal and Liver Physiology 2013, 304:G1117-G1127. 10.1152/ajpgi.00035.2013.
67. Geary N., Le Sauter J., Noh U. Glucagon acts in the liver to control spontaneous meal size in rats. American Journal of Physiology 1993, 264:R116-R122.
68. Tan T.M., Field B.C., McCullough K.A., Troke R.C., Chambers E.S., Salem V., et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013, 62:1131-1138. 10.2337/db12-0797.
69. Patterson M., Murphy K.G., Patel S.R., Patel N.A., Greenwood H.C., Cooke J.H., et al. Hypothalamic injection of oxyntomodulin suppresses circulating ghrelin-like immunoreactivity. Endocrinology 2009, 150:3513-3520. 10.1210/en.2008-0796.
70. Hagemann D., Holst J.J., Gethmann A., Banasch M., Schmidt W.E., Meier J.J. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regulatory Peptides 2007, 143:64-68.
71. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., et al. Ghrelin enhances appetite and increases food intake in humans. Journal of Clinical Endocrinology and Metabolism 2001, 86:5992.
72. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004, 89:2832-2836.
73. Day J.W., Smiley D., Carrington P.E., Eiermann G., Chicchi G., Erion M.D., et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Peptide Science 2012, 98:443-450. 10.1002/bip.22072.
74. Habegger K.M., Stemmer K., Cheng C., Müller T.D., Heppner K.M., Ottaway N., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013, 62:1453-1463. 10.2337/db12-1116.
75. Berglund E.D., Unger R.H. Role of fibroblast growth factor 21 in biology of glucagon. Diabetes 2013, 62:1376. 10.2337/db12-1840.
76. Arafat A.M., Kaczmarek P., Skrzypski M., Pruszyńska-Oszmalek E., Kołodziejski P., Szczepankiewicz D., et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?. Diabetologia 2013, 56:588-597. 10.1007/s00125-012-2803-y.
77. Adams A.C., Halstead C.A., Hansen B.C., Irizarry A.R., Martin J.A., Myers S.R., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 2013, 8:e65763.
78. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metabolism 2013, 18:333-340. 10.1016/j.cmet.2013.08.005.
79. Lin Z., Tian H., Lam K.S., Lin S., Hoo R.C., Konishi M., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metabolism 2013, 17:779-789. 10.1016/j.cmet.2013.04.005.
80. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567. 10.1016/j.cell.2011.11.062.
81. Adams A.C., Coskun T., Cheng C.C., Farrell O., Dubois L.S., Kharitonenkov S.L., A. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Molecular Metabolism 2013, 2:205-214. 10.1016/j.molmet.2013.05.005.
82. Engel S.S., Xu L., Andryuk P.J., Davies M.J., Amatruda J., Kaufman K., et al. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM). Diabetes 2011, 60(Suppl. 1):A85. 10.2337/db11-1-378.
83. Pradhan G., Samson S.L., Sun Y. Ghrelin: much more than a hunger hormone. Current Opinion in Clinical Nutrition & Metabolic Care 2013, 16:619-624. 10.1097/MCO.0b013e328365b9be.
84. Lockie S.H., Heppner K.M., Chaudhary N., Chabenne J.R., Morgan D.A., Veyrat-Durebex C., et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012, 61:2753-2762. 10.2337/db11-1556.
85. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. 10.1016/S0140-6736(08)61206-4.
86. Orskov C., Poulsen S.S., Møller M., Holst J.J. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996, 45:832-835.
87. Waldhäusl W., Haydl H., Nowotny P. ACTH and cortisol responses to glucagon stimulation. Journal of Clinical Endocrinology and Metabolism 1976, 43:675-678.
88. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156. 10.1053/j.gastro.2011.02.018.
89. Nauck M.A. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013, 36:2126-2132. 10.2337/dc12-2504.
90. Butler P.C., Elashoff M., Elashoff R., Gale E.A. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?. Diabetes Care 2013, 36:2118-2125. 10.2337/dc12-2713.
91. Eckhauser F.E., Knol J.A., Inman M.G., Strodel W.E. Efficacy of pharmacologic glucagon in acute experimental pancreatitis. Archives of Surgery 1985, 120:355-360.
92. Harada H., Kochi F., Hanafusa E., Kobayashi T., Oka H., Kimura I. Studies on the effect of glucagon on human pancreatic secretion by analysis of endoscopically obtained pure pancreatic juice. Gastroenterologia Japonica 1985, 20:28-36.
93. Girman C.J., Kou T.D., Cai B., Alexander C.M., O'Neill E.A., Williams-Herman D.E., et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes, Obesity and Metabolism 2010, 12:766-771.
94. Butler A.E., Campbell-Thompson M., Gurlo T., Dawson D.W., Atkinson M., Butler P.C. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013, 62:2595-2604. 10.2337/db12-1686.
95. Kahn S.E. Incretin therapy and islet pathology: a time for caution. Diabetes 2013, 62:2178-2180. 10.2337/db13-0520.
96. Heine R.J., Fu H., Kendall D.M., Moller D.E. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013, 62:e16-e17. 10.2337/db13-0690.
97. Engel S.S., Golm G.T., Lauring B. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013, 62:e18. 10.2337/db13-0525.
98. Bjerre Knudsen L., Madsen L.W., Andersen S., Almholt K., de Boer A.S., Drucker D.J., et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151:1473-1486. 10.1210/en.2009-1272.
99. Hegedüs L., Moses A.C., Zdravkovic M., Le Thi T., Daniels G.H. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism 2011, 96:853-860.
100. Gier B., Butler P.C., Lai C.K., Kirakossian D., DeNicola M.M., Yeh M.W. Glucagon like peptide-1 receptor expression in the human thyroid gland. Journal of Clinical Endocrinology and Metabolism 2012, 97:121-131. 10.1210/jc.2011-2407.
101. Crespel A., De Boisvilliers F., Gros L., Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996, 137:3674-3680.
102. Boden G., Rezvani I., Owen O.E. Effects of glucagon on plasma amino acids. Journal of Clinical Investigation 1984, 73:785-793.
103. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology 2009, 5:749-757. 10.1038/nchembio.209.
104. Barazzoni R., Zanetti M., Tiengo A., Tessari P. Protein metabolism in glucagonoma. Diabetologia 1999, 42:326-329.
105. Yabe D., Rokutan M., Miura Y., Komoto I., Usui R., Kuwata H., et al. Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: implications for glucagon-like peptide-1 secretion from pancreatic α cells in vivo. Diabetes Research and Clinical Practice 2013, 102:e1-e4. 10.1016/j.diabres.2013.08.005.
106. Nair K.S., Halliday D., Matthews D.E., Welle S.L. Hyperglucagonemia during insulin deficiency accelerates protein catabolism. American Journal of Physiology 1987, 253:E208-E213.
107. Buse M.G., Biggers J.F., Drier C., Buse J.F. The effect of epinephrine, glucagon, and the nutritional state on the oxidation of branched chain amino acids and pyruvate by isolated hearts and diaphragms of the rat. Journal of Biological Chemistry 1973, 248:697-706.
108. Farah A., Tuttle R. Studies on the pharmacology of glucagon. Journal of Pharmacology and Experimental Therapeutics 1960, 129:49-55.
109. Gonzalez-Munoz C., Nieto-Ceron S., Cabezas-Herrera J., Hernandez-Cascales J. Glucagon increases contractility in ventricle but not in atrium of the rat heart. European Journal of Pharmacology 2008, 587:243-247. 10.1016/j.ejphar.2008.04.001.
110. Grieve D.J., Cassidy R.S., Green B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. British Journal of Pharmacology 2009, 157:1340-1351. 10.1111/j.1476-5381.2009.00376.x.
111. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analog, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009, 26:268-278.
112. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
113. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
114. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
115. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., et al. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
116. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
117. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
118. Gill A., Hoogwerf B.J., Burger J., Bruce S., Macconell L., Yan P., et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovascular Diabetology 2010, 9:6.
119. Okerson T., Yan P., Stonehouse A., Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. American Journal of Hypertension 2010, 23:334-339.
120. Umpierrez G.E., Blevins T., Rosenstock J., Cheng C., Anderson J.H., Bastyr E.J. The effects of LY2189265, a long-acting glucagon-like peptide-1 analog, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes, Obesity and Metabolism 2011, 13:418-425. for the EGO Study Group.
121. Parmley W.W., Glick G., Sonneblick E.H. Cardiovascular effects of glucagon in man. New England Journal of Medicine 1968, 279:12-17.
122. Barbato A., Russo P., Venezia A., Strazzullo V., Siani A., Cappuccio F.P. Analysis of Gly40Ser polymorphism of the glucagon receptor (GCGR) gene in different ethnic groups. Journal of Human Hypertension 2003, 17:577-579. 10.1038/sj.jhh.1001591.
123. Strazzullo P., Iacone R., Siani A., Barba G., Russo O., Russo P., et al. Altered renal sodium handling and hypertension in men carrying the glucagon receptor gene (Gly40Ser) variant. Journal of Molecular Medicine 2001, 79:574-580. 10.1007/s001090100257.
124. Ruddy M., Luncenford J., Li S., Cilissen C., Stoch A., Wagner J., et al. Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy antagonist, MK-0893, in type 2 diabetes (T2DM). Diabetes 2011, 60(Suppl. 1):A85. 10.2337/ db11-1-378.
125. Panchapakesan U., Mather A., Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clinical Science 2013, 124:17-26. 10.1042/CS20120167.
126. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B. The SAVOR-TIMI 53 Steering Committee and Investigators: saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine 2013, 369:1317-1326. 10.1053/NEJMoa1307684.
127. Lao J., Hansen B.C., DiMarchi R., Pocai A. Effect of GLP1R/GCGR dual agonist in monkeys. Diabetes 2013, 62(Suppl. 1):A257. 10.2337/db13-859-1394.
128. Holst J.J. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Current Opinion in Pharmacology 2013, 13:00187-2. (pii: S1471-4892). 10.1016/j.coph.2013.09.014.
129. Chandarana K., Batterham R.L. Shedding pounds after going under the knife: metabolic insights from cutting the gut. Nature Medicine 2012, 18:668-669. 10.1038/nm.2748.
130. Garber A.J. Novel GLP-1 receptor agonists for diabetes. Expert Opinion on Investigational Drugs 2012, 21:45-57. (Review). 10.1517/13543784.2012.638282.
131. Kaspar A.A., Reichert J.M. Future directions for peptide therapeutics development. Drug Discovery Today 2013, 18:807-817. 10.1016/j.drudis.2013.05.011.
132. Lee K.C., Chae S.Y., Kim T.H., Lee S., Lee E.S., Youn Y.S. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regulatory Peptides 2009, 152:101-107. 10.1016/j.regpep.2008.09.008.
133. Owens D.R. New horizons - alternative routes for insulin therapy. Nature Reviews. Drug Discovery 2002, 1:529-540. 10.1038/nrd836.
134. Sloop K.W., Willard F.S., Brenner M.B., Ficorilli J., Valasek K., Showalter A.D., et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 2010, 59:3099-3107. 10.2337/db10-0689.
135. Finan B., Ma T., Ottaway N., Müller T.D., Habegger K.M., Heppner K.M., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine 2013, 5:209ra151. 10.1126/scitranslmed.3007218.
136. Kerr B.D., Flatt P.R., Gault V.A. D-Ser2)Oxm(mPEG-PAL): a novel chemically modified analog of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochemical Pharmacology 2010, 80:1727-1735. 10.1016/j.bcp.2010.08.010.
137. Liu Y.L., Ford H.E., Druce M.R., Minnion J.S., Field B.C., Shillito J.C., et al. Subcutaneous oxyntomodulin analog administration reduces body weight in lean and obese rodents. International Journal of Obesity 2010, 34:1715-1725. 10.1038/ijo.2010.110.
138. Bhat V.K., Kerr B.D., Flatt P.R., Gault V.A. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochemical Pharmacology 2013, 85:1655-1662. 10.1016/j.bcp.2013.03.009.
139. Bhat V.K., Kerr B.D., Vasu S., Flatt P.R., Gault V.A. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia 2013, 56:1417-1424. 10.1007/s00125-013-2892-2.
140. Roed S.N., Orgaard A., Jorgensen R., De Meyts P. Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity. Frontiers in Endocrinology 2012, 3:62. 10.3389/fendo.2012.00062.
141. Schelshorn D., Joly F., Mutel S., Hampe C., Breton B., Mutel V., Lutjens R. Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Molecular Pharmacology 2012, 81:309-318. 10.1124/mol.111.074757.
142. Meier J.J., Goetze O., Anstipp J., Hagemann D., Holst J.J., Schmidt W.E., et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. American Journal of Physiology - Endocrinology and Metabolism 2004, 286:E621-E625.
143. Henry R.R., Rosenstock J., Logan D.K., Alessi T.R., Luskey K., Baron M.A. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care 2013, 36:2559-2565. 10.2337/dc12-2410.
144. Vignini A., Giulietti A., Nanetti L., Raffaelli F., Giusti L., Mazzanti L., Provinciali L. Alzheimer's disease and diabetes: new insights and unifying therapies. Current Diabetes Review 2013, 9:218-227. (Review).
145. Rekha M.R., Sharma C.P. Oral delivery of therapeutic protein/peptide for diabetes--future perspectives. International Journal of Pharmaceutics 2013, 440:48-62. 10.1016/j.ijpharm.2012.03.056.
146. Astrup A., Carraro R., Finer N., Harper A., Kunesova M., Lean M.E., et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity 2012, 36:843-854. 10.1038/ijo.2011.158.
147. Kielgast U., Krarup T., Holst J.J., Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 34:1463-1468. 10.2337/dc11-0096.
148. Amiel S.A., Tamborlane W.V., Simonson D.C., Sherwin R.S. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. New England Journal of Medicine 1987, 316:1376-1383. 10.1056/nejm198705283162205.
149. Cryer P.E. The barrier of hypoglycemia in diabetes. Diabetes 2008, 57:3169-3176. 10.2337/db08-1084.